KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-Asian populations. Therefore, it is necessary to carry out studies in other populations to confirm the diagnostic values of the biomarker and its prognostic implication. Hypothesis KL-6 may be a useful biomarker in the management of interstitial lung diseases. But it is necessary to know more about its utility in the European population. Study Objectives: * To determine the concentration of KL-6 in serum of patients with pulmonary fibrosis at the time of diagnosis compared to patients without pulmonary fibrosis * Diagnostic yield of KL-6 in patients with pulmonary fibrosis. * Correlation of KL-6 values with functional and radiological parameters of disease severity at diagnosis. * Correlation of serum KL-6 values with the evolution of the disease.
Study Type
OBSERVATIONAL
Enrollment
250
Measure of KL-6 in serum
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
RECRUITINGSerum KL-6 levels in patients with pulmonary fibrosis at the time of diagnosis.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.